X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NE3107 is an ERK/NF-kappa B Inhibitor small molecule drug candidate, which is currently being evaluated for mild to moderate Alzheimer’s Disease treatment.
Lead Product(s): NE3107
Therapeutic Area: Neurology Product Name: NE3107
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
NE3107 is an oral small molecule, with potential anti-inflammatory, insulin sensitizing, and ERK-binding properties which allows it to selectively inhibit ERK-, NFκB- and TNF-stimulated inflammation.
Lead Product(s): NE3107
Therapeutic Area: Neurology Product Name: NE3107
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
BIV201 (terlipressin diacetate), a vasopressin agonist, it increases systemic vascular resistance, particularly in the splanchnic area, resulting in a decrease of portal pressure. It reduces ascites fluid buildup.
Lead Product(s): Terlipressin Acetate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: BIV201
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2023
Details:
NE3107 is an oral small molecule, with potential anti-inflammatory, insulin sensitizing, and ERK-binding properties which allows it to selectively inhibit ERK-, NFκB- and TNF-stimulated inflammation.
Lead Product(s): NE3107
Therapeutic Area: Neurology Product Name: NE3107
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
NE3107 is an oral small molecule, with potential anti-inflammatory, insulin sensitizing, and ERK-binding properties which allows it to selectively inhibit ERK-, NFκB- and TNF-stimulated inflammation.
Lead Product(s): NE3107
Therapeutic Area: Neurology Product Name: NE3107
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2023
Details:
NE3107 showed potential to enhance cognition, 2.2 point improvement on ADAS-Cog12 scale equating to 21.1% compared to baseline, 0.11 point improvement on CDR scale, equating 19.4% change from baseline, and 0.07 point improvement in ADCOMS scale, equating to 27.4% improvement.
Lead Product(s): NE3107
Therapeutic Area: Neurology Product Name: NE3107
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2022
Details:
NE3107 is an oral small molecule, blood-brain permeable, compound with potential anti-inflammatory, insulin sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK-, NFκB- and TNF-stimulated inflammation.
Lead Product(s): NE3107
Therapeutic Area: Neurology Product Name: NE3107
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2022
Details:
NE3107 is an oral small molecule, blood-brain permeable, compound with potential anti-inflammatory, insulin sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK-, NFκB- and TNF-stimulated inflammation.
Lead Product(s): NE3107
Therapeutic Area: Neurology Product Name: NE3107
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2022
Details:
NE3107 is an oral small molecule that is a blood-brain permeable compound with potential anti-inflammatory, insulin sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK- and NFκB-stimulated inflammation.
Lead Product(s): NE3107
Therapeutic Area: Neurology Product Name: NE3107
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
NE3107 is associated with significant improvements in cognition as evidenced by the ADAS-Cog12 scale. 82% of 17 patients with MMSE >=20 experienced a 2.6 point decrease in ADAS-Cog12 (p=0.0046).
Lead Product(s): NE3107
Therapeutic Area: Neurology Product Name: NE3107
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
